Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

64.50 +2.37 (+3.81%)
Streaming Delayed Price Updated: 3:20 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 ↗
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily
News headline image
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
Sarepta Therapeutics Stock Shows Improved Technical Strength ↗
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition ↗
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now. 
Via InvestorPlace
News headline image
NASDAQ:HALO is not too expensive for the growth it is showing. ↗
NASDAQ:HALO stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
9 Analysts Have This To Say About Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
In the world of growth stocks, NASDAQ:HALO shines as a value proposition. ↗
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. 
Via Chartmill
News headline image
NASDAQ:HALO, a strong growth stock, setting up for a breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket ↗
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results. 
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy in Q2 2024 ↗
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Preview: Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
News headline image
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease ↗
Michael Shpigelmacher, Founder and CEO of Bionaut Labs, with the company’s micro-robot designed to swim through the central nervous system into the brain to treat disease now on trial in the U.S. 
Via Benzinga
News headline image
NASDAQ:HALO, an undervalued stock with good fundamentals. ↗
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued. 
Via Chartmill
News headline image
NASDAQ:HALO, a strong growth stock, setting up for a breakout. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
NASDAQ:HALO: good value for what you're paying. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Earnings Scheduled For February 20, 2024 ↗
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
News headline image
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients ↗
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo. 
Via Benzinga
News headline image
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗
In the world of growth stocks, NASDAQ:HALO shines as a value proposition. 
Via Chartmill
News headline image
3 Biotech Stocks to Sell in January Before They Crash and Burn ↗
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell. 
Via InvestorPlace
News headline image
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion ↗
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.